Solace Stress Urinary inContinence Control Efficacy and Safety Study

NACompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

August 11, 2014

Primary Completion Date

December 18, 2015

Study Completion Date

March 30, 2019

Conditions
Stress Urinary Incontinence
Interventions
DEVICE

Solace Bladder Control (Vesair) Balloon

Subjects may undergo treatment every 12 months until study completion.

DEVICE

Solace Sham Treatment

Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon

Trial Locations (20)

11021

North Shore LIJ, Great Neck

12550

Premier Medical Group, Newburgh

12601

Premier Medical Group, Poughkeepsie

21061

Chesapeake Urology, Glen Burnie

21117

Chesapeake Urology, Owings Mills

23233

Virginia Women's Center, Richmond

23462

Urology of Virginia, Virginia Beach

27103

Lyndhurst Clinical Research, Winston-Salem

29425

MUSC Urology, Charleston

49503

Female Pelvic Medicine and Urogynecology Institute of Michigan, Grand Rapids

57105

Sanford Female Pelvic Medicine and Reconstructive Surgery Clinic, Sioux Falls

60004

WomanCare, Arlington Heights

60453

Women's Health Institute of Illinois, Oak Lawn

71106

Regional Urology, Shreveport

80220

Genitourinary Surgical Consultants, Denver

85016

Valley Urogynecology Associates, Phoenix

85715

Urological Associates of Southern Arizona, Tucson

98043

Integrity Medical Research, Mountlake Terrace

06850

Urology Associates of Norwalk, Norwalk

02905

Women and Infants Hospital, Providence

All Listed Sponsors
lead

Solace Therapeutics, Inc.

INDUSTRY

NCT02210273 - Solace Stress Urinary inContinence Control Efficacy and Safety Study | Biotech Hunter | Biotech Hunter